Dr. Crystal L. Mackall, co-leader of the SU2C-St. Baldrick’s Pediatric Cancer Dream Team
Dr. Crystal Mackall and Dr. John Maris will co-chair the SU2C-St. Baldrick’s Foundation Immunogenomics Dream Team.
Mackall is an internationally recognized expert in human immunology and has led a cutting-edge translational immunotherapy research program for pediatric sarcomas. She is credited with fundamental discoveries regarding T cell homeostasis and has led the clinical development of recombinant human IL-7, the most potent immunorestorative identified thus far. As Chief of the Pediatric Oncology Branch at the NCI, she leads a diverse translational research program focused on the most challenging of pediatric cancers, and also serves on numerous steering committees and advisory boards focused on translational research.
From a long list of innovative “big ideas,” the scientific reviewers representing both funding organizations had chosen the top four to submit detailed proposals. The experts agreed that any of these would be great investments, but for a grant of $14.5 million over four years, only one could be chosen.
The suspense ended with an enthusiastic round of applause when the winning Dream Team was announced at a reception tonight at the annual meeting of the American Association of Cancer Research (AACR). The evening’s emcee was actor Kyle MacLachlan, and speakers included Nobel Laureate Dr. Philip Sharp, St. Baldrick’s CEO Kathleen Ruddy, and 10-year-old cancer survivor Emma W. and her parents.
And the award goes to: